ClinicalTrials.gg
Active, not recruitingNCT07019480Updated Jun 13, 2025

Influence of Implant Insertion Torque on Post-Surgical Marginal Bone Stability

An observational study in Edentulous Alveolar Ridge, sponsored by International Piezosurgery Academy. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-13.

Sponsored by International Piezosurgery Academy · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this prospective, multicenter observational study is to evaluate the influence of various surgical parameters (maximum insertion torque; average insertion torque; final insertion torque; area under the torque curve; intercept and slope of the least squares regression line of the torque curve; implant stability quotient measured immediately after implant insertion) on implant osseointegration and on peri-implant marginal bone loss occurring during the first three months of submerged healing.

Read the detailed description

This proposed study is a prospective, observational multicenter clinical trial. Ten independent clinical centers will treat partially edentulous patients with dental implants following a specific surgical protocol.

Enrollment Procedure: All patients meeting the inclusion and exclusion criteria will be enrolled in the study after receiving the Information Sheet and providing written informed consent.

Pre-surgical planning will be performed using a CBCT scan with or without the aid of dedicated image reconstruction software. A preoperative periapical radiograph will also be taken using a customized Rinn-type film holder for each patient, with the aid of a silicone key.

Surgical phase: After local anesthesia with 4% articaine containing 1:100,000 epinephrine, a minimally invasive full-thickness mucoperiosteal flap will be elevated to visualize the crest anatomy. The height of the supracrestal soft tissue will be measured using a dedicated probe (SSL, Medesy, Maniago, Italy) and categorized as thin (\<2.5 mm), medium (2.5-3.5 mm), or thick (>3.5 mm).

Implant site preparation will be carried out using a dedicated surgical kit (Anyone, Megagen, Gyeongbuk, South Korea). The implant (Anyone, 4.0×8.5 mm) will then be placed at crestal level, with torque values recorded throughout the entire insertion process using a surgical motor set to 30 rpm (Implantmed, W\&H, Burmoos, Austria). The maximum torque will be limited to 80 Ncm.

If the maximum torque is insufficient to complete insertion, the implant will be removed and the site will be further prepared using the next drill in the sequence.

After crestal-level placement, Patients will be prescribed an NSAID (ibuprofimplant stability (ISQ) will be measured in the mesio-distal, disto-mesial, bucco-lingual, and linguo-buccal directions using a resonance frequency analysis device (Osstell Beacon, Osstell, Göteborg, Sweden) with a single-use magnetic peg specific to the implant (SmartPeg Type 07, Osstell, Göteborg, Sweden). Calibration of the device must be verified prior to each patient procedure using an implant secured in a resin block.

The flap will be closed using non-resorbable monofilament sutures, and the implant will be submerged (two-stage protocol). A periapical radiograph will be taken at this point (T0) using the previously described customized Rinn-type holder. en 600 mg, as needed) and instructed to rinse with 0.2% chlorhexidine mouthwash for two minutes, three times per day, starting on the second postoperative day.

Sutures will be removed 7-10 days after surgery.

Post-surgical follow-ups: After three months of healing (T1), a periapical radiograph will be taken using the previously described customized holder, and a second-stage surgery will be performed to uncover the implant. Following ISQ measurement as previously described, a definitive transmucosal abutment of appropriate length and diameter (OCTA, Megagen, Gyeongbuk, South Korea) will be connected. After a four-week healing period, an abutment-level impression will be taken for the fabrication of the final prosthesis, which may be either a single screw-retained metal-ceramic crown or a screw-retained bridge.

Periapical radiographic follow-ups will be performed as described above at prosthesis delivery and at 6 months, 1 year, 3 years, and 5 years post-loading to assess marginal bone stability.

Radiographic Measurements: All radiographs will be taken using identical radiographic device settings (60 kV, 7 mA). Peri-implant bone levels (PBL) will be measured at T0 and T1 as the linear distance between the implant platform and the bone crest at the mesial and distal aspects of each implant. A positive value will be assigned when the bone crest is coronal to the implant platform, while a negative value will be recorded when the first bone-to-implant contact is apical to the implant platform.

The difference in PBL between T0 and T1 will represent marginal bone loss if PBL_T1 \< PBL_T0, and marginal bone gain if PBL_T1 > PBL_T0. Measurements will be calibrated according to the known implant diameter and length.

Any radiograph showing distortion and/or other quality issues must be immediately retaken.

All measurements will be performed by two blinded examiners using image analysis software (ImageJ 1.52a, National Institutes of Health, Bethesda, MD, USA) on a 24-inch medical-grade monitor. Each measurement will be repeated three times at three different time points, as proposed by Gomez-Roman and Launer.

Examiner calibration will be carried out on a sample of ten radiographs not included in the study. The Cohen's kappa coefficient (k) will be calculated by a third investigator to assess intra-examiner and inter-examiner agreement.

Statistical Analysis: Descriptive statistics will be used to summarize the baseline characteristics of the study population. The relationship between insertion torque and marginal bone loss will be assessed using regression models, adjusting for potential confounding variables. Repeated measures ANOVA will be used to analyze ISQ changes over time. A p-value \<0.05 will be considered statistically significant. Data analysis will be performed using SPSS Statistics v25.0 (IBM Corp., Armonk, NY, USA).

Sample Size Calculation: The sample size was calculated based on a previously published study (Marconcini S, Longitudinal analysis on the effect of insertion torque on delayed single implants: A 3-year randomized clinical study. Clin Implant Dent Relat Res. 2018;20(3):322-332.), which reported a one-year failure rate of 1.72% (1/58) in the low insertion torque group (\<50 Ncm) and 3.45% (2/58) in the high insertion torque group (≥ 50 Ncm). A 1:1 allocation ratio was considered, with a significance level of 0.01 and statistical power of 90%. The minimum required sample size was 68 implants (34 per group). To compensate for potential drop-outs and to allow for repeated measures analysis, 150 implants will be placed across 10 clinical centers (15 implants per center). Each patient may contribute up to 3 implants.

02

Conditions studied

  • Edentulous Alveolar Ridge
03

In context

Lead sponsor

International Piezosurgery Academy is the lead sponsor of 24 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

After investigating general and local anamnesis, which included evaluation of systemic illnesses and potential allergies, a dental visit was conducted to formulate a specific treatment plan.

If the patient was deemed eligible for the research protocol, an additional periapical radiograph was obtained for each selected site to assess the adequacy of residual bone height.

If the available bone height appeared to be sufficient, a second-level radiographic exam, a Cone Beam Computed Tomography (CBCT), was performed to evaluate whether the bone volume was adequate for supporting implant rehabilitation.

For patients requiring tooth extraction, this second assessment was performed after six months of healing after extraction.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Indication for implant-supported prosthetic rehabilitation of single or multiple partial edentulism in one or both arches, based on accurate diagnosis and treatment planning;
  • The area in which the implants will be placed must have had at least 6 months of healing;
  • Residual alveolar ridge width ≥7 mm;
  • Available bone height >9 mm at the planned implant site;
  • Patient aged >18 years;
  • Patient does not use any removable prosthesis at the site to be treated;
  • Patient is able and willing to comply with the study protocol;
  • Patient signs the written .

Exclusion criteria

Exclusion Criteria:

  • Acute myocardial infarction within the past two months;
  • Uncontrolled bleeding disorders;
  • Uncontrolled diabetes ( > 7.5);
  • History of head and/or neck radiotherapy within the past 24 months;
  • patients, positive, or undergoing chemotherapy within the past five years;
  • Current or previous antiresorptive therapy;
  • Psychological or psychiatric disorders;
  • Drug or alcohol abuse.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Target follow-up
6 Years
Patient registry
Yes

Groups and cohorts

  • cohort

    implant insertion with recorded torque and stability values

    Procedure: implant insertion

Interventions

  • Procedureimplant insertion

    Following local anesthesia (articaine 4% with epinephrine 1:100,000), a minimally invasive full-thickness flap will be elevated. Implant site preparation will be performed with twist drills and the implant will be inserted. Implant stability (ISQ) will be measured in the mesio-distal, disto-mesial, bucco-lingual, and linguo-buccal directions using a resonance frequency analysis device (Osstell Beacon, Osstell, Göteborg, Sweden) with a single-use magnetic peg specific to the implant (SmartPeg Type 07, Osstell, Göteborg, Sweden). The flap will be closed using non-resorbable monofilament sutures, and the implant will be submerged (two-stage protocol).

06

What researchers measure

Primary outcomes

  1. Implant Stability Quotient (ISQ) for the evaluation of primary stability, measured using a resonance frequency analysis (RFA) device (Osstell).

    Resonance Frequency Analysis (RFA) device (Osstell, Göteborg, Sweden) with the appropriate transducer for the selected abutment (Smartpeg Type 05, Osstell, Göteborg, Sweden). ISQ will be measure in the mesio-distal, disto-mesial, bucco-lingual, and linguo-buccal directions.

    Time frame: Immediately after implant placement

  2. Implant primary stability in Newton

    Insertion torque

    Time frame: During the full course of implant insertion

  3. Periapical radiograph for the assessment of peri-implant bone level (PBL) in millimeters

    Periapical radiograph using a customized Rinn-type film holder for each patient with the aid of a silicone index

    Time frame: Immediately after implant placement

Secondary outcomes

  1. Implant Stability Quotient (ISQ) for the evaluation of secondary stability, measured using a resonance frequency analysis (RFA) device (Osstell)

    Resonance Frequency Analysis (RFA) device (Osstell, Göteborg, Sweden) with the appropriate transducer for the selected abutment (Smartpeg Type 05, Osstell, Göteborg, Sweden). ISQ will be measure in the mesio-distal, disto-mesial, bucco-lingual, and linguo-buccal directions.

    Time frame: 3 months after implant insertion

  2. Periapical radiograph for the assessment of peri-implant bone level (PBL) in millimeters

    Periapical radiograph using a customized Rinn-type film holder for each patient with the aid of a silicone index

    Time frame: 3 months after implant insertion

  3. Periapical radiograph for the assessment of peri-implant bone level (PBL) in millimeters

    Periapical radiograph using a customized Rinn-type film holder for each patient with the aid of a silicone index

    Time frame: upon prosthesis delivery

  4. Periapical radiograph for the assessment of peri-implant bone level (PBL) in millimeters

    Periapical radiograph using a customized Rinn-type film holder for each patient with the aid of a silicone index

    Time frame: 6 months after prosthetic loading

  5. Periapical radiograph for the assessment of peri-implant bone level (PBL) in millimeters

    Periapical radiograph using a customized Rinn-type film holder for each patient with the aid of a silicone index

    Time frame: 1 year after prosthetic loading

  6. Periapical radiograph for the assessment of peri-implant bone level (PBL) in millimeters

    Periapical radiograph using a customized Rinn-type film holder for each patient with the aid of a silicone index

    Time frame: 3 years after prosthetic loading

  7. Periapical radiograph for the assessment of peri-implant bone level (PBL) in millimeters

    Periapical radiograph using a customized Rinn-type film holder for each patient with the aid of a silicone index

    Time frame: 5 years after prosthetic loading

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Dec 2031, 83 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 13, 2025
StartActual
Jan 1, 2025
Primary completionEst.
Dec 31, 2031
CompletionEst.
Dec 31, 2035
Last update
Jun 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07019480
Lead sponsor
International Piezosurgery Academy
Collaborators
University of Trieste
Responsible party
Sponsor
First posted
Jun 13, 2025
Start date
Jan 1, 2025
Primary completion
Dec 31, 2031 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Jun 13, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion